RESUMEN
Aims: The purpose of this randomized controlled clinical trial was to clinically assess soft tissue augmentation and compare patients' morbidity and root coverage outcomes of coronally advanced flap (CAF) with subepithelial connective tissue graft (SCTG) versus de-epithelialized free gingival graft (DFGG) in the management of Miller Class I and II gingival recession. Materials and Methods: Twenty-eight patients with Miller's Class I or II gingival recession (GR) defects were randomly assigned into two equal parallel groups treated with either CAF + SCTG, harvested using single-line incision technique (control), or CAF + DFGG (test). Gingival thickness (GT), recession depth, recession width, percentage of root coverage, keratinized tissue width, pocket depth, and clinical attachment level were measured at baseline and 3 and 6 months postoperatively. Patient-reported outcomes were assessed postoperatively, including pain, stress, bleeding, and inability to chew. Patients' overall satisfaction and root coverage esthetic scores were recorded at 6 months. Results: Both groups demonstrated a statistically significant improvement in all clinical outcomes after 3 and 6 months compared to baseline. DFGG showed a statistically significant increase in GT after 6 months. No statistically significant difference was detected in other clinical outcomes between both groups at different time intervals. Both treatments achieved 92.9% complete root coverage. Patients treated with CAF + DFGG reported significantly higher stress and inability to chew scores after 2 weeks than those treated with SCTG. There were no significant differences in patient satisfaction between both groups. Conclusions: CAF + SCTG and CAF + DFGG were both effective and can be applied safely in treating Miller Class I and II GRs.
RESUMEN
AIM: This study aimed to compare the effect of MEBO versus 0.2% hyaluronic acid gel (Gengigel®) applied to the palatal donor site on postoperative pain reduction and wound healing after free gingival graft harvesting. Methodology. Thirty-nine patients with different mucogingival defects were included in this study for harvesting a free gingival graft (FGG) for soft tissue augmentation. Patients were randomly assigned into three equal groups: group I (MEBO), group II (0.2% HA Gengigel®), and group III (control). Postoperative pain was recorded by using the Visual Analogue Scale (VAS). Analgesic consumption was recorded for 7 days postoperatively. Wound size was measured at baseline and on days 3, 7, 14, and 21. Postoperative healing of the palatal wound was assessed by the VAS score for color match on days 3, 7, 14, 21, and 42. RESULTS: Results of this study showed significant postoperative pain reduction for the three groups; MEBO showed statistically significant less VAS score compared to the other two groups, while HA showed statistically significant less VAS score compared to the control group. Both MEBO and HA showed statistically significant less total analgesic consumption. No statistically significant difference was observed between groups for wound size. MEBO showed statistically significant higher VAS for color match. CONCLUSIONS: Both treatment modalities could reduce postoperative pain following harvesting of FGG and improve the palatal wound healing. However, MEBO showed better outcomes in terms of postoperative pain and color match.
RESUMEN
OBJECTIVE: The objective is to determine the effect of oral zinc supplement intake on the clinical efficacy and sustained effect of BTXA injection, in patients with excessive gingival display (EGD). MATERIALS AND METHODS: Twenty-five participants with excessive gingival display (EGD) were included in this parallel-group RCT, treated with BTXA with and without Zinc supplementation prior to treatment. Participants were assessed for excessive gingival display reduction and results of stability at 2, 6, 12, 18, and 24 weeks. Patient satisfaction questionnaires were filled at 2, 12, and 24 weeks. RESULTS: The results of this study revealed that after 6, 12, 18, as well as 24 weeks; The control group (BTXA) showed statistically significantly higher median gingival display than the intervention (Zinc supplement with BTXA). In the intervention group, the median gingival display after 24 weeks showed statistically significantly lower median value compared to the baseline measurement CONCLUSIONS: The use of zinc supplementation prior to BTXA injection prolonged its effect and maintained long-term decreased amount of gingival display, and it did not return to baseline measurements. Patients reported high satisfaction levels and self-confidence. CLINICAL RELEVANCE: Botulinum Toxin A (BTXA) is used to correct gummy smile; however, its main drawback is its short-lasting effect. Oral zinc supplement intake prior to BTXA injection could maintain the effect of BTXA and enhance its clinical efficacy.
